2 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
The following table sets forth information regarding compensation awarded to or earned by our named executive officers.
Name and Principal Position | Year | Salary ($) | Bonus ($) | Option Awards ($) (1) | Total ($) | |||||||||||||
Michael Davidson, M.D. | 2023 | 569,000 | 313,000 | 4,923,558 | 5,832,558 | |||||||||||||
Chief Executive Officer (2) | ||||||||||||||||||
John Kastelein, M.D., Ph.D. FESC | 2023 | 459,346 | (3) | 218,412 | 2,300,813 | 2,978,571 | ||||||||||||
Chief Scientific Officer (4) | ||||||||||||||||||
Ian Somaiya | 2023 | 90,576 | 40,000 | 3,422,493 | 3,553,069 | |||||||||||||
Chief Financial Officer (5) |
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
The following table sets forth information regarding compensation awarded to or earned by our named executive officers.
Name and Principal Position | Year | Salary ($) | Bonus ($) | Option Awards ($) (1) | Total ($) | |||||
Michael Davidson, M.D. | 2023 | 569,000 | 313,000 | 4,923,558 | 5,832,558 | |||||
Chief Executive Officer (2) | ||||||||||
John Kastelein, M.D., Ph.D. FESC | 2023 | 459,346 (3) | 218,412 | 2,300,813 | 2,978,571 | |||||
Chief Scientific Officer (4) | ||||||||||
Ian Somaiya | 2023 | 90,576 | 40,000 | 3,422,493 | 3,553,069 | |||||
Chief Financial Officer (5) |
- Prev
- 1
- Next